Tessa Romero
Stock Analyst at JP Morgan
(2.17)
# 1096
Out of 5,243 analysts
61
Total ratings
45.24%
Success rate
39.39%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Upstream Bio | Initiates Coverage On: Overweight | 38 | 11.71 | 224.51% | 1 | Nov 5, 2024 | |
Neumora Therapeutics | Downgrades: Neutral | 18 15 | 2.17 | 591.24% | 4 | Nov 5, 2024 | |
Dyne Therapeutics | Downgrades: Neutral | 43 35 | 15.7 | 122.93% | 4 | Oct 24, 2024 | |
Seres Therapeutics | Downgrades: Underweight | n/a | n/a | n/a | 2 | Oct 24, 2024 | |
Scholar Rock Holding | Maintains: Overweight | 18 31 | 43.38 | -28.54% | 5 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 55 68 | 36.22 | 87.74% | 5 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 71 | 47.53 | 49.38% | 4 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 32 29 | 7.38 | 292.95% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 31 | 28.7 | 8.01% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 46 | 33.86 | 35.85% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 29 25 | 17.46 | 43.18% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 5.63 | 255.24% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 8 7 | 6.44 | 8.7% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 54 55 | 40.78 | 34.87% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 39 36 | n/a | n/a | 4 | Jun 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 140 150 | n/a | n/a | 1 | Mar 2, 2021 |